21:46 , Mar 29, 2019 |  BC Extra  |  Financial News

Blueprint raises $300M in follow-on, speeds regulatory timelines

Days after revealing new timelines for its lead program, Blueprint raised $300 million in a follow-on priced late Thursday. Blueprint Medicines Corp. (NASDAQ:BPMC) sold 4.1 million shares at $74, a 7% discount to the company's...
17:38 , Jan 11, 2019 |  BC Week In Review  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
15:12 , Jan 7, 2019 |  BC Extra  |  Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
22:58 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Rival RET inhibitor data highlighted at thyroid meeting

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat RET-altered cancers....
20:32 , Oct 8, 2018 |  BC Extra  |  Clinical News

Rival RET inhibitor data highlighted at thyroid meeting

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data on Saturday at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat...
15:00 , Jun 29, 2018 |  BC Week In Review  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies....
20:18 , Jun 27, 2018 |  BC Extra  |  Company News

CStone gets Chinese rights to Agios' ivosidenib

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) gained exclusive rights from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to develop and commercialize ivosidenib (AG-120) in China, including Hong Kong and Macau, and Taiwan as monotherapy or in combination therapies....
16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
22:12 , Jun 4, 2018 |  BC Extra  |  Company News

CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...